Ultrasonographic Assessment of Preoperative Metoclopramide on Gastric Volume in Diabetic Patients: A Prospective Controlled Study
Journal of Cellular and Molecular Anesthesia · 05.05.2026 · 11 (2)
DOI: 10.5812/jcma-171078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Anesthesia, online erschienen am 05.05.2026. Verfasst von Mahmoud Fawzy Elsharkawy und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Diabetic gastroparesis due to autonomic neuropathy and chronic hyperglycemia impairs gastric motility and may persist despite standard preoperative fasting, increasing perioperative aspiration risk. Point-of-care (POC) gastric ultrasound allows objective, real-time bedside assessment of gastric residual volume (GRV) before anesthetic induction.
Objectives
This study evaluated whether a single preoperative dose of intravenous (IV) metoclopramide reduces antral cross-sectional area (CSA) and aspiration risk in fasted diabetic patients undergoing elective surgery under general anesthesia.
Methods
This prospective, non-randomized controlled study included 60 patients divided into three groups (n = 20 each): Group I (diabetics receiving IV metoclopramide 10 mg, 30 - 60 minutes before ultrasound), Group II (diabetics without intervention), and Group III (non-diabetic controls). After at least 8 hours of fasting, POC gastric ultrasound was performed in semi-sitting (SS) and right lateral decubitus (RLD) positions. The primary outcome was antral CSA (cm²); secondary outcomes included GRV (mL), antral gastric grade (AGG), weight-adjusted GRV (mL/kg), and post-intervention fasting glucose.
Results
Antral CSA was lower in metoclopramide-treated diabetics versus untreated diabetics and approached non-diabetic controls. Gastric residual volume decreased in treated versus untreated diabetics and was comparable to controls. Antral gastric grade 0 occurred in 60% of treated diabetics versus 25% of untreated diabetics and 90% of controls (χ² = 17.3, P < 0.001). Grade 2 appeared only in diabetics (10% treated, 20% untreated). Weight-adjusted GRV was lower in treated versus untreated diabetics. Post-intervention fasting glucose differed across groups (P < 0.001).
Conclusions
Preoperative IV metoclopramide (10 mg) significantly reduces antral CSA and GRV in fasted diabetic patients, partially normalizing gastric parameters toward non-diabetic levels and lowering aspiration risk.
Zitieren
APA
Elsharkawy, M. F., Shams, G. H., Algyar, M., Beshir, H., & Hefny, D. A. E. S. E. (2026). Ultrasonographic Assessment of Preoperative Metoclopramide on Gastric Volume in Diabetic Patients: A Prospective Controlled Study. Journal of Cellular and Molecular Anesthesia, 11(2). https://doi.org/10.5812/jcma-171078
Vancouver
Elsharkawy MF, Shams GH, Algyar M, Beshir H, Hefny DAESE. Ultrasonographic Assessment of Preoperative Metoclopramide on Gastric Volume in Diabetic Patients: A Prospective Controlled Study. Journal of Cellular and Molecular Anesthesia. 2026;11(2). doi:10.5812/jcma-171078
BibTeX
@article{Elsharkawy2026,
author = {Elsharkawy, Mahmoud Fawzy and Shams, Gamal Hendawy and Algyar, Mohammad and Beshir, Hameda and Hefny, Daila Ahmed El Sayed El},
title = {Ultrasonographic Assessment of Preoperative Metoclopramide on Gastric Volume in Diabetic Patients: A Prospective Controlled Study},
journal = {Journal of Cellular and Molecular Anesthesia},
year = {2026},
volume = {11},
number = {2},
doi = {10.5812/jcma-171078}
}
EUVIMED